Gathering the record
Relay is organizing the evidence and source boundaries.
Synthetic tripeptide
An experimental peptide discussed for blood-vessel health and related symptoms. It is not FDA approved.
Evidence is explained by question. Dosing references show their own check dates.
60-second overview
Why people look into it, what studies found, and what is still unknown.
Educational information only. Evidence reviewed through July 31, 2026. Published studies, sponsor announcements, and trials without results are labeled separately. Evidence gaps apply to the specific finding beside them.
Research questions
Each label shows how much evidence supports that question.
What studies show
A 41-patient clinical report evaluated KED in vasculogenic erectile dysfunction without the safeguards of a large modern randomized trial.
This is the strongest human-evidence boundary in the current record.
Mechanistic findings explain biological plausibility; they do not establish a human outcome.
Relay keeps this uncertainty visible rather than converting it into a prediction.
The safety snapshot reflects the studied record and its limitations.
Regulatory and identity status determine how the evidence should be interpreted.
Risks & unknowns
Relay has not verified a clear pattern of side effects for this compound.
Evidence boundaryHuman exposure is present, but the record is not detailed enough to characterize a reliable adverse-event pattern.
The available information does not reliably show how often particular side effects occur.
Evidence boundaryUnder-detected or under-reported events must not be described as rare.
Relay has not verified which side effects led people to stop treatment in studies.
Evidence boundaryThis is an evidence gap, not proof that discontinuations did not occur.
Relay has not verified a compound-specific warning summary for this profile.
Evidence boundaryNot FDA-approved; limited regional human evidence. Whether findings reproduce under blinded randomized conditions and translate to validated vascular outcomes.
This profile does not contain verified, product-specific emergency instructions.
Evidence boundaryRelay does not infer emergency guidance from study discontinuations, mechanism, or incomplete adverse-event reporting.
Dosing references
Each table labels its source and applies only to the named route, product, or study. An online example or community report is not an approved dose.
Small regional human reports are represented, but their accessible abstracts do not establish a complete, formulation-matched dosing method.
What would fill this gap: Full primary methods confirming KED identity, formulation, route, amount, and schedule.
Dosing review checked Oct 20, 2026. Additional sources are available below.No route-specific preparation instructions were verified. A different route or product does not supply them.
Starting dose: the amount used at the beginning of the named label schedule or trial.
Maintenance: the ongoing amount described by that product label.
Trial target: the amount assigned to a study group. Different groups may stop increasing at different targets.
A small clinical report investigated KED-containing treatment in men with vasculogenic erectile dysfunction and measured clinical and laboratory outcomes.
Population: Men with vasculogenic erectile dysfunction
Design: Small clinical study without robust placebo control
Mechanisms
A small report in vasculogenic erectile dysfunction and cell-aging experiments provide early signals. Neither establishes broad vascular rejuvenation or product equivalence.
A plausible mechanism can explain why a study was attempted. It does not prove that the compound improves a human outcome.
No single validated target is established in the current record.
Research reference
A reference for the studies, populations, and routes behind this profile.
Small uncontrolled or weakly controlled human evidence plus laboratory studies.
Research depth describes how large and mature the overall record is. It does not tell you whether the results were positive.
Whether findings reproduce under blinded randomized conditions and translate to validated vascular outcomes.
Confidence describes how reliable and consistent the conclusions are. It can be high for one outcome and low for another.
The strongest evidence type shows what the best-supported conclusions are actually based on.
Human findings are more directly relevant than animal or laboratory results, but they still apply only to the populations and outcomes studied.
Route-specific record
These are exposures used in cited research for a specific route and population—not an instruction for an individual.
Half-life describes how long it takes the measured amount in the body to fall by half. It is not a dosing recommendation.
Evidence can change by administration method. Findings from one route should not automatically be applied to another.
Evidence boundary: The study was small, regional, and did not use a robust blinded placebo-controlled design. It cannot establish a causal KED effect, general vascular benefit, product equivalence, or long-term safety. Amounts shown describe cited research exposure—not a dosage recommendation.
Studies
Study arms are reported for transparency. They describe what researchers did in a defined record and do not transfer across identities, routes, formulations, or populations.
A later trial phase can ask a more mature question, but it does not guarantee a positive result, regulatory approval, or relevance outside the studied population.
Small clinical study without robust placebo control
Men with vasculogenic erectile dysfunction
A 41-patient report described clinical and laboratory outcomes after KED-containing treatment.
Study administration: Not stated in the current record.
Limitations: Small, regional, incompletely controlled report; requires independent randomized replication.
Human-cell culture study
Population not stated.
Endpoints were not fully described in the current record.
KED-related laboratory work explored gene and chromatin markers in cultured cells.
Study administration: Not stated in the current record.
Limitations: Mechanistic cell evidence is not a clinical vascular outcome.
Community
Built by the community
Every structured report adds useful context about research setup, outcomes, and unwanted effects as the community dataset grows.
Publicly anonymous by default. Your account keeps reports editable and helps reduce duplicate submissions.Sources
PMID 25051774
PMID 25051766